Cargando…
Effect of Dexamethasone on the Incidence and Outcome of COVID-19 Associated Pulmonary Aspergillosis (CAPA) in Critically Ill Patients during First- and Second Pandemic Wave—A Single Center Experience
Superinfections with Aspergillus spp. in patients with Coronavirus disease 2019 (CAPA: COVID-19-associated pulmonary aspergillosis) are increasing. Dexamethasone has shown beneficial effects in critically ill COVID-19 patients. Whether dexamethasone increases the risk of CAPA has not been studied ex...
Autores principales: | Dubler, Simon, Turan, Ömer Can, Schmidt, Karsten Daniel, rath, Peter-michael, Verhasselt, Hedda-Luise, Maier, Sandra, Skarabis, Annabell, Brenner, Thorsten, Herbstreit, Frank |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777363/ https://www.ncbi.nlm.nih.gov/pubmed/36553055 http://dx.doi.org/10.3390/diagnostics12123049 |
Ejemplares similares
-
Characteristics of Critically Ill Patients with COVID-19 Compared to Patients with Influenza—A Single Center Experience
por: Herbstreit, Frank, et al.
Publicado: (2021) -
COVID-19-Associated Pulmonary Aspergillosis (CAPA)
por: Dimopoulos, George, et al.
Publicado: (2021) -
Microbiological Non-Culture-Based Methods for Diagnosing Invasive Pulmonary Aspergillosis in ICU Patients
por: Scharmann, Ulrike, et al.
Publicado: (2023) -
Regional Impact of COVID-19-Associated Pulmonary Aspergillosis (CAPA) during the First Wave
por: Bentvelsen, Robbert G., et al.
Publicado: (2022) -
COVID‐19‐associated pulmonary aspergillosis in ICU patients in a German reference centre: Phenotypic and molecular characterisation of Aspergillus fumigatus isolates
por: Kirchhoff, Lisa, et al.
Publicado: (2022)